Developing new antibiotic treatments, promoting responsible use, and ensuring access for all
The Global Antibiotic Research & Development Partnership (GARDP) was established in May 2016 as a joint initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi). The mission of this not-for-profit research and development (R&D) initiative is to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all in need.
A partnership model for product development, based on the experience gained from the field of neglected diseases, can provide an important element of the overall strategy for R&D in the field of antibiotics. Such a partnership can test new incentives that also contribute to conservation of and access to new antibiotic treatments. By doing so, it can provide an important alternative to the traditional market-driven pharmaceutical approach, by focusing on products that the pharmaceutical industry will likely not develop for lack of profitability.
GARDP works closely with all stakeholders in the field of antibiotic R&D – including pharmaceutical and biotechnology companies, startups, other product development partnerships, academia, civil society, and health authorities – from countries of all income levels – to develop new antibiotic treatments.
- addresses global public health and specific needs of low- and middle-income countries;
- targets products that industry will likely not develop due to lack of profitability or other reasons;
- pilots the use of alternative incentive models delinking cost of R&D from volume-based sales and prices of antibiotics, which support conservation of and access to new antibiotics; and
- ensures that new antibiotics developed by GARDP are affordable to all in need.
To ensure that GARDP focuses its scientific portfolio towards meeting priority needs, its R&D prioritization process begins with the requirement that any programme meets at least two out of three key criteria:
1. Target priority pathogens
2. Address priority diseases and syndromes
3. Help under-served priority patient populations
GARDP’s objectives: 2017-2023
- Develop and deliver up to four new treatments through improvement of existing antibiotics and acceleration of the entry of new chemical entities. Build a robust pipeline of pre-clinical and clinical candidates with up to four candidates brought into pre-clinical or clinical development.
- Secure EUR 270 million to execute its R&D programmes, build a highly experienced R&D team, and establish a dedicated entity.
- Support and advocate for appropriate use of antibiotics, sustainable access, and suitable financing of R&D for new antibiotic treatments.